[ad_1]
A technician at Regeneron Pharmaceuticals headquarters in Tarrytown, New York.
Facebook Facebook logo Register on Facebook to communicate with Mike Segar Reuters
Regeneron and Roche are teaming up on an experimental antibody cocktail against Covid-19, with the American company to sell it in the United States and the Swiss drugmaker to sell it elsewhere, if the drug is approved.
Regeneron said it was awaiting initial data from ongoing trials of its Covid-19 antibody cocktail, called REGN-COV2, next month.
The drug, among several developed by drugmakers seeking a treatment for the novel coronavirus, has prevented and treated disease in rhesus macaques and hamsters, Regeneron said this month.
Together with Roche, Regeneron aims to increase the overall production capacity of REGN-COV2 by at least three and a half times to meet potential US and global needs. Roche’s decision to partner with Regeneron comes after its own drug, Actemra, failed in a lawsuit against Covid-19.
“REGN-COV2 could provide a much needed treatment option for people already showing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thereby slowing the spread of the global pandemic,” Roche said in a statement.
The companies will jointly fund and manage ongoing Phase 3, Phase 3 and Phase 1 prevention studies on the safety of healthy Phase 1 volunteers, as well as additional global studies to further assess REGN-COV2 for treatment or prevention of Covid-19, Roche said.
[ad_2]
Source link